Catalog No.
PHJ16701
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human STING1/TMEM173 (Leu139-Ser379).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
STING1,Stimulator of interferon genes protein,Endoplasmic reticulum interferon stimulator,Transmembrane protein 173,ERIS,hSTING,TMEM173,Mediator of IRF3 activation,MITA,hMITA
Purification
Purified by antigen affinity column.
Accession
Q86WV6
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
A Multi-Threshold Micelle Improves Tumor Accumulation and STING Immunotherapy., PMID:40439216
Nanoimmunomodulation of the Aβ-STING feedback machinery in microglia for Alzheimer's disease treatment., PMID:40434641
Reprogramming tumor-associated macrophages using STING or TLR agonists: a promising strategy to enhance immunotherapy in hormone-dependent cancers., PMID:40379270
[Buzhong Yiqi Decoction alleviates immune injury of autoimmune thyroiditis in NOD.H-2~(h4)mice via c GAS-STING signaling pathway]., PMID:40350879
The emerging concept of ANCA-associated vasculitis related to inborn errors of immunity., PMID:40294837
[Effects of lipopolysaccharide-activated interferon gene stimulator signaling on periodontal ligament cells]., PMID:40268534
STING agonist-based ER-targeting molecules boost antigen cross-presentation., PMID:40140567
Dual-modality immune nano-activator harnessing Mn2⁺ and quercetin to potentiate the cGAS-STING pathway for advanced cancer metalloimmunotherapy., PMID:40128784
Regulation and Function of the cGAS-STING Pathway: Mechanisms, Post-Translational Modifications, and Therapeutic Potential in Immunotherapy., PMID:40098909
Enhanced therapeutic efficacy of anti-PD-1 blockade by targeting LAMP2A inhibits lysosomal degradation of STING and TBK1., PMID:40083918
PCK1 inhibits cGAS-STING activation by consumption of GTP to promote tumor immune evasion., PMID:40048154
ADSL-generated fumarate binds and inhibits STING to promote tumour immune evasion., PMID:40033100
XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells., PMID:40029253
STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia., PMID:40009483
Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING-Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy., PMID:40007227
TAX1BP1-dependent autophagic degradation of STING1 impairs anti-tumor immunity., PMID:40000606
Zinc-copper bimetallic nanoplatforms trigger photothermal-amplified cuproptosis and cGAS-STING activation for enhancing triple-negative breast cancer immunotherapy., PMID:39994712
Inhibitors of soluble epoxide hydrolase and cGAS/STING repair defects in amyloid-β clearance underlying vascular complications of Alzheimer's disease., PMID:39962970
STING activation and overcoming the challenges associated with STING agonists using ADC (antibody-drug conjugate) and other delivery systems., PMID:39922441
Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody-Drug Conjugate TAK-500., PMID:39918395
Chemotherapy boosts anti-angiogenic and anti-PD-1 combination therapy through activation of cCAS-STING pathway in colon cancer., PMID:39904029
Immune checkpoint inhibitors mediate myocarditis by promoting macrophage polarization via cGAS/STING pathway., PMID:39884185
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas., PMID:39846804
Activating the cGAS-STING Pathway by Manganese-Based Nanoparticles Combined with Platinum-Based Nanoparticles for Enhanced Ovarian Cancer Immunotherapy., PMID:39846241
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors., PMID:39817655
Personalized Nanovaccine Based on STING-Activating Nanocarrier for Robust Cancer Immunotherapy., PMID:39817337
STING Agonist VB-85247 Induces Durable Antitumor Immune Responses by Intravesical Administration in a Non-Muscle-Invasive Bladder Cancer., PMID:39700406
Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma., PMID:39658648
Role of STING Deficiency in Amelioration of Mouse Models of Lupus and Atherosclerosis., PMID:39605244
Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy., PMID:39548120
Bendamustine-rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS-STING activation in diffuse large B-cell lymphoma., PMID:39521616
Bidirectional regulation of the cGAS-STING pathway in the immunosuppressive tumor microenvironment and its association with immunotherapy., PMID:39464890
Targeting STING signaling for the optimal cancer immunotherapy., PMID:39450170
Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells., PMID:39449023
Robust and Sustained STING Pathway Activation via Hydrogel-Based In Situ Vaccination for Cancer Immunotherapy., PMID:39405469
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses., PMID:39401968
Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model., PMID:39353433
DKN-01 Suppresses Gastric Cancer Progression Through Activating cGAS-STING Pathway to Block Macrophage M2 Polarization., PMID:39352454
Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway., PMID:39237260
Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS-STING Pathway in Triple-Negative Breast Cancer Cells., PMID:39226389
Microglial cGAS-STING signaling underlies glaucoma pathogenesis., PMID:39190350
Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy., PMID:39180916
Metal-Phenolic Vehicles Potentiate Cycle-Cascade Activation of Pyroptosis and cGAS-STING Pathway for Tumor Immunotherapy., PMID:39155444
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration., PMID:39113096
Circulating cell-free DNA promotes inflammation in dermatomyositis patients with anti-NXP2 antibodies via the cGAS/STING pathway., PMID:39110532
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy., PMID:39060021
Tetrandrine activates STING/TBK1/IRF3 pathway to potentiate anti-PD-1 immunotherapy efficacy in non-small cell lung cancer., PMID:39059614
A polymeric nanoplatform enhances the cGAS-STING pathway in macrophages to potentiate phagocytosis for cancer immunotherapy., PMID:39038546
Activation of autoreactive lymphocytes in the lung by radioresistant cells expressing a STING gain-of-function mutation., PMID:39024563
A High Immune-Related Index with the Suppression of cGAS-STING Pathway is a Key Determinant to Herceptin Resistance in HER2+ Breast Cancer., PMID:38993569
For research use only. Not for human or drug use.
